Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC).
Clin Transl Oncol
; 10(4): 198-203, 2008 Apr.
Article
em En
| MEDLINE
| ID: mdl-18411192
Lung cancer is a leading cause of death worldwide and, although some progress has been made in its treatment, the results remain poor. Better knowledge in tumour biology has allowed us to design anti-target drugs and incorporate them in the treatment of non-small-cell lung cancer (NSCLC). One of the most widely used targeted approaches in this type of tumour has been the inhibition of angiogenesis. Several strategies blocking the VEGF pathway, either at the ligand or recepor level, have been studied and developed. In this review, we present an up-to-date analysis of the current inhibitors of angiogenesis in the treatment of NSCLC.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores da Angiogênese
/
Neoplasias Pulmonares
/
Neovascularização Patológica
Limite:
Humans
Idioma:
En
Revista:
Clin Transl Oncol
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Espanha
País de publicação:
Itália